The study reveals significant metabolic changes in the VAT of obese APP/PS1 mice and highlights Andro's potential as a therapeutic agent for addressing VAT impairment induced by obesity in AD. This evidence concerns the gene APP and obesity due to melanocortin 4 receptor deficiency.